Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + ISIS 183750 + paclitaxel
- Development stage
- Unknown
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of three agents:\n- **Carboplatin** is a platinum-based chemotherapeutic that induces DNA crosslinking and apoptosis in rapidly dividing cells.\n- **Paclitaxel** (Taxol) is a microtubule-stabilizing agent that inhibits cell division by preventing microtubule depolymerization.\n- **ISIS 183750** is an antisense oligonucleotide targeting insulin-like growth factor type I receptor (IGF1R) mRNA to reduce its expression. \nThe combination of carboplatin and paclitaxel is widely used for the treatment of various solid tumors including ovarian cancer, non-small cell lung cancer, endometrial cancer, cervical cancer, carcinoma of unknown primary origin, thymoma or thymic carcinoma[1][3][5]. The addition of ISIS 183750 aims to enhance antitumor activity by inhibiting IGF1R-mediated signaling pathways involved in tumor growth and survival.
- Other names
- carboplatinpaclitaxelISIS 183750ISIS183750ISIS-183750
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNAEIF4E (Eukaryotic translation initiation factor 4E)
Beyond the preview
Go deeper on carboplatin + ISIS 183750 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + ISIS 183750 + paclitaxel.